The official of the FDA vaccine Peter Marks joins RFK Jr.
Dr. Peter Marks, director of the Center for Biological Affairs and Research within Food and Drug Administration, answers a question during a hearing on the health, educational and pension committee of the Senate to discuss the continuous federal response to Covid-19 in the US Capitol in Washington, DC on May 11, 2021.
Greg Nash | Pool | Reuters
Peter Marks Peter Mark The Food and Drug Administration of the Food and Drug Administration has resigned, according to a letter of withdrawal obtained from CNBC, Robert F. Kennedy Jr.s “Misery and Lies”, Robert F. Kennedy Jr.
For almost 10 years, Marks headed the FDA Center for Biological Affairs and Research, a contribution that included the evaluation of COVID-19 vaccines and the determination of guidelines for aspiring treatments such as cell and gene therapies. An important number at the FDA, the insiders of the Biopharma industry, were exactly the markings in the middle of the transition.
The Wall Street Journal for the first time reported Marks's resignation and said that an official from the Ministry of Health and Human Services gave Marks the opportunity to resign or be released. Marks, the FDA and the Ministry of Health and Human Services did not immediately respond to a request for comments.
In his letter of withdrawal, which was aimed at the incumbent FDA commissioner Sara Brenner, Marks praised the work of the agency to accelerate the development of vaccines, which the quality standards, security, the effectiveness awaited by Americans and “undoubtedly significantly reduced morbidity and mortality of cowid-19 in the United States and otherwise” and otherwise “described the efforts that Disadvantaged health effects of immunization “in relation to” in relation to the negative effects of immunization “in relation to current measles outbursts as an example of the” clear danger “of the” undermining trust in well -established vaccines “.
“As you know, I was ready to work myself to visit the secretary's concerns about the security and transparency of the vaccine by the public and to implement a variety of different public meetings and commitment with the National Academy of Sciences, Engineering and Medicine,” wrote Marks. “However, it has become clear that truth and transparency are not desired by the secretary, but he wants submissive confirmation of his misinformation and lies.”
Marks was known in the Biopharma industry to find regularly at conferences about the search for ways to accelerate the development of innovative therapies, especially for rare diseases. His departure could continue to shake a biotech industry that has been depressed in recent years.
Last autumn, Marks spoke to the distance on the Jefferies London Healthcare Conference, he planned to stay as long as he was welcome.
“I will stay nearby as long as I stayed as welcome,” said Marks at the time, according to Endpoints News. “I think it is very important that people see that there are always leadership – that we are here to work with both sides of the gang.”
